Cutaneous Melanoma Clinical Trials in Cleveland, Ohio

4 studies are recruiting for cutaneous melanoma in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  2. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Cleveland Clinic Foundation, Cleveland, Ohio
    Locations
    15 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT03947385 on ClinicalTrials.gov

  3. A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

    KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, r…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    15 in total
    Run by
    Krystal Biotech, Inc.

    See if you can join NCT05970497 on ClinicalTrials.gov

  4. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Cleveland Clinic, Cleveland, Ohio
    Locations
    11 in total
    Run by
    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.